A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome Leukemia (2007) A 35-year-old female patient with Noonan Syndrome (NS) presented with leukocytosis and splenomegaly. Aged 13, she had undergone surgery for severe pulmonary valve stenosis with right-to-left atrial shunt. Recent medical history included malaise, lack of appetite and moderately painful, tender red nodules with central ulceration on face, neck and arms. Skin biopsy showed marked oedema and superficial and deep derma granulocyte infiltration, with some eosinophils. Blood counts were: white blood cells, 386 Â 10 9 /l (neutrophils 55%, lymphocytes 7%, monocytes 34%, eosinophils 4%); haemoglobin: 13.5 g/dl; platelets, 336 Â 10 9 /l. Chronic myelomonocytic leukaemia (CMML) was diagnosed on bone marrow aspirate. Karyotype, described according to the International System for Human Cytogenetic Nomenclature, 1995, was 46,XX, t(5; 16)(q33; p13) [11]/46,XX [4] (Figure 1a) .
In all cells bearing t(5;16)(q33;p13), fluorescent in situ hybridization (FISH) indicated PDGFRB was rearranged ( Figure 1b) . Investigations on the 16p13 breakpoint revealed that DNA clones for 3 0 CBP (cosmids RT191/RT203), 5 0 CBP (cosmids RT166/RT53), NDE1 (CTD-2303E13) and 3 0 MYH11 (cosmids ZIT27/ZIT29) were translocated to der(5). The 5 0 MYH11 (cosmids ZIT14/ZIT18 and clone RP11-844E20) and the entire MRP gene (clone RP11-8H13) were deleted (Figure 1c and d). FISH investigation into anthracycline resistance-associated (ARA) gene, as the next centromeric candidate, gave disappointing results. Experiments with clones RP11-517A5, RP11-958N24, RP11-148M17 had to be discarded upon closer sequence analysis (BLAST algorithm, at www.ncbi.nlm.nih.gov/ BLAST) which revealed duplicated or triplicated DNA inserts in the 16p13 region centromeric to NDE1 and MYH11. Consequently, spurious signals could have masked deletion of each probe's target region. DNA clones more centromeric to RP11-148M17 (from RP11-14N3 to RP11-696K16) were retained on der(16) (Figure 1c) . Therefore, the 3 0 MYH11 and the NDE1 gene set the telomeric boundary of the 16p deletion, whereas the 700 kb multiple-copy region included the ARA gene and the undefined centromeric boundary.
As FISH at the 5q33 breakpoint showed a PDGFRB rearrangement, imatinib mesylate was started. After six months, the patient achieved hematological and FISH remission and skin lesions disappeared, confirming findings in another patient with myeloproliferative disorder, cutaneous involvement and t(5;12)(q33;q13) with rearranged PDGFRB.
1
Platelet derived growth factor receptor beta (PDGFRb) tyrosine kinase is expressed in hematopoietic cells, fibroblasts, endothelial cells and osteoblasts and plays a pre-eminent role in monocytic differentiation, vascular repair, tissue inflammation and wound healing. PDGFRB/5q33 balanced translocations identify a subgroup of CMML and atypical chronic myeloid leukaemia presenting, predominantly in males, with bone marrow and/or peripheral blood eosinophilia and splenomegaly. As a result of this translocation, the 3 0 region of PDGFRB encoding the kinase domain fuses with the 5 0 region of a partner gene encoding an oligomerization domain, thus consti-tutively activating PDGFRb tyrosine kinase. At least 11 PDGFRB gene partners are known; several others remain unidentified, including one partner(s) located at 16p13 (Blood 2004; 104: abstract 2902) .
In our patient, candidates as PDGFRB gene partners were selected on the basis of FISH findings. MYH11 was incorrectly oriented and had lost its 5 0 end. ARA was also incorrectly oriented and reverse transcriptase-polymerase chain reaction (RT-PCR) excluded ARA/PDGFRB and PDGFRB/ARA fusions (data not shown). As NDE1 was in the correct orientation and contained an N-terminal oligomerization domain, we sought an NDE1/PDGFRB fusion. Amplifying the NDE1/PDGFRB transcript by RT-PCR yielded a specific product which, upon sequencing, showed in-frame fusion of NDE1 exon 5 (GenBank no. NM_017668) with PDGFRB exon 11 (GenBank no. NM_002609) (Figure 1e ). NDE1/PDGFRb is predicted to contain the 174 amino acids (including the oligomerization domain) of the NDE1 N-terminal fused to the C-terminal transmembrane and split tyrosine kinase domains of PDGFRb. Amplification and sequencing of the der(5) genomic breakpoint confirmed NDE1 intron 5 and PDGFRB intron 10 were fused (Genbank accession no. DQ317513).
NDE1 is a centrosomal protein regulating dynein-mediated transport of kinetocore proteins to spindle poles along microtubules and contributes to spindle checkpoint inactivation in mitosis.
2,3 Truncated forms of NDE1 induce mitotic arrest in 293T cells, possibly by interfering with wild-type NDE1 oligomerization.
3 NDE1 is disrupted in 90% of CBFB/ MYH11 positive acute myeloblastic leukaemia (AML) in humans and in mice haploinsufficiency or NDE1 ablation is associated with onset of a MDS-like syndrome (Blood 2004; 104: abstract 61) . Prompted by these data we sequenced the unrearranged NDE1 cDNA but found no mutations (data not shown). 
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Figure 1
Cytogenetic, FISH and molecular studies of t(5;16)(q33;p13) breakpoints. (a) G-banded partial karyotypes of the patient showing the t(5;16)(q33;p13). (b) FISH with cosmid 9-4 (red) for the 3 0 PDGFRB and cosmid 4-1 (green) for the 5 0 PDGFRB give a red/green fusion signal on normal chromosome 5, a red signal on der(5) (arrow) and a green signal on der(16) (arrow). (c) The 16p13 region, DNA clones and FISH findings. þ , present; À, absent. (d) Double colour FISH with cosmids ZIT27/ZIT29 (green) and cosmids ZIT14/ZIT18 (red) give a red/green fusion signal on normal chromosome 16 and a green signal on der(5) (arrow). (e) Nucleotide sequence showing the fusion point (arrowhead) between NDE1 exon 5 and PDGFRB exon 11.
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Phosphorylated NDE1-PDGFRb transformed Ba/F3 cells to IL3 independent growth, indicating it was a constitutively active tyrosine kinase (Figure 2a and b) . Ba/F3 cell proliferation was inhibited by imatinib mesylate (Figure 2c ), in keeping with our patient's response to imatinib therapy.
Denaturing high-performance liquid chromatography analysis identified a G 178 4T (NM_002834) nucleotide germline substitution in exon 3 of PTPN11, which given our patient's phenotype, is most probably the congenital cause of NS. 4 As far as we know this is the first observation of a germline PTPN11 mutation leading to Gly60Cys amino acid substitution. PTPN11 encodes phosphatase and adaptor protein SHP-2 (src homology region 2-domain phosphatase-2), which is a modulator of intracellular signalling from a number of growth factor receptors, including PDGFRb. Germline mutations of the PTPN11 gene are found in 40-60% of NS whereas acquired mutations characterize roughly 30% of Juvenile Chronic Myelomonocytic Leukaemia. Interestingly, acquired PTPN11 mutations concomitant with tyrosine kinase mutations, namely FLT3-ITD and FLT3-TKD mutations, have been reported in a few cases of acute lymphoblastic Leukaemia and AML.
5,6
Our study shows for the first time a case of CMML with an NDE1/PDGFRB fusion in addition to a missense mutation in exon 3 0 of PTPN11 underlying NS. The PTPN11 gain-of-function mutation in association with the constitutively phosphorylated tyrosine kinase NDE1/PDGFRB may have triggered CMML in this patient with NS. The vast majority of patients with chronic myelogeneous leukemia (CML) (495%) has a breakpoint in the M-bcr, resulting in b3-a2, b2-a3, b2-a2 or b3-a3 fusion gene transcripts and the associated p210 BCR-ABL protein. 1 In rare cases of CML, the breakpoint in BCR is located in the m-bcr, resulting in an e1-a2 or e1-a3 fusion gene transcript and associated p190 protein or in the m-bcr region, resulting in an e19-a2 fusion gene transcript and the associated p230 protein. Some unusual breakpoints have been described in CML as well, including cases with transcripts derived from fusion genes in which the breaks are located within exons and cases with transcripts in which intronic sequences are inserted.
Acknowledgements
1 Here, we present a 16-year old girl with CML who showed a new type of fusion gene transcript, containing part of BCR exon 18 linked to ABL exon 2, with insertion of 10 nucleotides from intron 1b at the joining site.
A 16-year old girl was admitted to the hospital because of fatigue, headache and visual abnormalities. Liver and spleen enlargement were found at physical examination. Laboratory investigation showed a hemoglobin of 4 mmol/l, a white blood cell count (WBC) of 399 Â 10 9 /l and a platelet count of 698 Â 10 9 /l. Morphologic evaluation of peripheral blood showed 4% basophils, 3% eosinophils, o1% monocytes, 2% lymphocytes, 5% blasts and 86% myeloid cells at different stages of maturation. The Sokal score was 1.57 (high risk) and the Euro score was 1459 (intermediate risk). Karyotyping showed 46,XX,t(9;22)(q34;q11) in all metaphases. The presence of a BCR-ABL fusion gene was confirmed with FISH (BCR/ABL ES probe set, Vysis). In addition, an accompanying deletion of a part of ABL was detected in the der(9)t(9;22) by this assay. Based on these findings, a diagnosis of CML in chronic phase was established.
Treatment was started with leucapheresis and hydroxyurea. After 2 weeks, the WBC had dropped to normal values and treatment was switched to imatinib 600 mg/day, according to the Dutch Childhood Oncology Group CML protocol (imatinib dose: 400 mg/m 2 /day). Because of thrombocytopenia, imatinib was dose-reduced to 400 mg/day at day þ 37. At day þ 56 from diagnosis the patient was in complete hematological remission. Cytogenetic analysis of the bone marrow showed 41% t(9;22)-positive metaphases. FISH analysis showed the BCR-ABL fusion in 29% of interphase cells. A major cytogenetic response was established at day þ 106 with 6% t(9;22) positive metaphases. At that time, a real-time quantitative (RQ)Fpolymerase chain reaction (PCR) analysis using the primer-probe set developed within the Europe Against Cancer program 2 was performed on the diagnostic specimen as well as the bone marrow sample taken at day þ 106. This RQ-PCR showed an unexpectedly low amplification in the diagnostic sample and could not detect BCR-ABL fusion gene transcripts in the day þ 106 bone marrow. This prompted us to analyze the BCR-ABL fusion gene transcript in more detail. Therefore, PCR analysis was performed using the BIOMED-1 primer set (primer BCR-b1-A and ABL-a3-B).
3 This resulted in a PCR product of approximately 800 bp, in contrast to the p210 positive control (BV173) showing the expected PCR product of 400 bp. The PCR product of the patient was cut out of the gel, sequenced, and the obtained sequence was aligned with the germline BCR and ABL sequences (accession numbers: BCR: U07000; ABL: U07563). This showed that the fusion gene transcript in the patient contained part of exon 18 of the BCR gene (the first 90 nucleotides, the last 20 nucleotides being deleted), an insertion of 10 nucleotides, followed by exon 2 of the ABL gene (Figure 1) . The breakpoint at the DNA level was analyzed by ligation-mediated PCR. 4 This showed that exon 18 of BCR was coupled to the first 423 bp of intron 1b downstream of ABL exon 2, resulting in a putative splice site (Figure 1) .
The new in-frame e18-a2 BCR-ABL transcript is 390 base pairs larger than the e14-a2 transcript (M-Bcr) and is predicted to encode a protein 130 amino acids longer than the p210 protein. Western blot analysis, using an ABL antibody (8E9), indeed showed the presence of a protein with a molecular mass of approximately 225 kDa (data not shown). Wild-type BCR-ABL protein (p210) was not found, which is in line with the lack of a normal BCR-ABL fusion transcript. Using a flow cytometric immunobead assay (Weerkamp et al., Haematologica 2006; 91(s1) :377, abstract), BCR-ABL protein was detected as well (data not shown). It should be noted that the predicted e18-a2 BCR-ABL protein contains exactly the same ABL domains as the p210 (and p190) protein, suggesting that imatinib binding will not be affected.
Based on the identified fusion gene transcript, an exon 18 specific forward primer was designed (5 0 -AGGATGCCGTCCC GAAA-3 0 ). In combination with the EAC reverse primer and probe, this resulted in a good amplification of the e18-intron 1b-a2 fusion gene transcript. MRD analysis of the day þ 106 bone marrow sample using this newly designed RQ-PCR showed a tumor load of 2 Â 10 À2 (Table 1) . MRD analysis of a bone marrow sample obtained at day þ 210 showed a further reduction of the tumor load to 2 Â 10
À3
. At day þ 239, the imatinib dose was escalated to 600 mg without recurrence of hematological toxicity. MRD analysis at day þ 285, day þ 377, and day þ 474 showed that the tumor load in the bone marrow remained relatively stable around a level of approximately 1 Â 10 À3 (Table 1) . Imatinib therapy will be continued and regular follow-up for the occurrence of resistance is planned.
To our knowledge, only seven CML patients in whom transcripts are derived from fusion genes in which the breaks are located within exons have been described so far. In two of these patients (a 65-year-old male and a 59-year-old male), the unusual transcript consisted of 86 base pairs of BCR exon 15 joined in frame with ABL exon 2 at nucleotide 78.
5 These transcripts could only be identified upon nested PCR approaches
